PMID- 16954562
OWN - NLM
STAT- MEDLINE
DCOM- 20061024
LR  - 20220316
IS  - 0161-5505 (Print)
IS  - 0161-5505 (Linking)
VI  - 47
IP  - 9
DP  - 2006 Sep
TI  - Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast 
      cancer cells in vitro.
PG  - 1525-30
AB  - Mutations in the p53 gene, often resulting in loss of wild-type (WT) p53 
      expression, are found at high frequencies in several cancer types. High uptake of 
      (18)F-FDG detected using (18)F-FDG PET has been associated with a poor prognosis. 
      To determine whether high (18)F-FDG uptake may be related to decreased expression 
      of WT p53, we examined (18)F-FDG uptake in cells transfected with dominant 
      negative p53 constructs that abrogate WT p53 function. METHODS: Two clones of 
      MCF-7 breast cancer cells were stably transfected with a dominant negative p53 
      construct. (18)F-FDG uptake, hexokinase (HK) activity, and glucose transport were 
      measured in each clone and in the control WT cells from which the clones had been 
      derived. The expression of glucose transporters, HKs, and glucose-6-phosphatase 
      was determined using microarray technology. RESULTS: Microarray experiments 
      revealed that glucose transporters 1, 8, and 10 were expressed in MCF-7 cells, 
      whereas glucose-6-phosphatase was absent. HK I was the principal HK in MCF-7 
      cells but was not differentially expressed at the messenger RNA level in the 
      dominant negative p53 clones, compared with WT cells. However, increased HK 
      activity was observed in both dominant negative p53 clones, compared with WT 
      MCF-7. (18)F-FDG uptake was increased in both clones expressing the dominant 
      negative p53 constructs. CONCLUSION: These data suggest that abrogation of p53 in 
      breast cancer is associated with specific changes in glucose metabolism detected 
      by PET.
FAU - Smith, Tim A D
AU  - Smith TA
AD  - Department of Biomedical Physics, School of Medical Sciences, University of 
      Aberdeen, Foresterhill, Aberdeen, United Kingdom. t.smith@biomed.abdn.ac.uk
FAU - Sharma, Rituka I
AU  - Sharma RI
FAU - Thompson, Alastair M
AU  - Thompson AM
FAU - Paulin, Fiona E M
AU  - Paulin FE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Nucl Med
JT  - Journal of nuclear medicine : official publication, Society of Nuclear Medicine
JID - 0217410
RN  - 0 (Radiopharmaceuticals)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Breast Neoplasms/*diagnostic imaging/*metabolism
MH  - Cell Line, Tumor
MH  - Down-Regulation
MH  - Fluorodeoxyglucose F18/*pharmacokinetics
MH  - Humans
MH  - Metabolic Clearance Rate
MH  - Radionuclide Imaging
MH  - Radiopharmaceuticals/pharmacokinetics
MH  - Tumor Suppressor Protein p53/*metabolism
EDAT- 2006/09/07 09:00
MHDA- 2006/10/25 09:00
CRDT- 2006/09/07 09:00
PHST- 2006/09/07 09:00 [pubmed]
PHST- 2006/10/25 09:00 [medline]
PHST- 2006/09/07 09:00 [entrez]
AID - 47/9/1525 [pii]
PST - ppublish
SO  - J Nucl Med. 2006 Sep;47(9):1525-30.